Provided by Tiger Fintech (Singapore) Pte. Ltd.

Elevation Oncology, Inc.

0.5100
-0.0001-0.02%
Volume:659.90K
Turnover:334.19K
Market Cap:30.15M
PE:-0.65
High:0.5300
Open:0.4996
Low:0.4910
Close:0.5101
Loading ...

Elevation Oncology- Sees to Initiate Dosing in Combination Portion of Phase 1 Trial of Eo-3021 in 4Q

THOMSON REUTERS
·
06 Nov 2024

Elevation Oncology Q3 Basic EPS USD -0.22

THOMSON REUTERS
·
06 Nov 2024

Press Release: Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements

Dow Jones
·
06 Nov 2024

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
31 Oct 2024

AstraZeneca Receives CHMP's Approval for Wainzua in Europe

Zacks
·
23 Oct 2024

EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies

Zacks
·
22 Oct 2024

SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies

Zacks
·
18 Oct 2024

Empery Asset Management's Strategic Acquisition in Elevation Oncology

GuruFocus.com
·
10 Oct 2024

Elevation Oncology Gets FDA Fast-Track Designation for EO-3021

Dow Jones
·
23 Sep 2024

Elevation Oncology Receives Fast Track Designation From the FDA for Eo-3021 for the Treatment of Adult Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2

THOMSON REUTERS
·
23 Sep 2024

Elevation Oncology: Look to Advancing Through Monotherapy Dose Expansion, Reporting More Data From Ongoing Trial in H1 2025

THOMSON REUTERS
·
23 Sep 2024

Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2

PR Newswire
·
23 Sep 2024

BRIEF-Elevation Oncology On Sept 18, Got Notice From Nasdaq On Co's Failure To Satisfy A Continued Listing Rule Or Standard

Reuters
·
21 Sep 2024

Elevation Oncology Inc - on Sept18, Got Notice From Nasdaq on Co's Failure to Satisfy a Continued Listing Rule or Standard

THOMSON REUTERS
·
21 Sep 2024